Vasculera in Participants With Lipedema

The goal of this type of clinical trial is to compare the measurement of participants legs before treatment and after using the treatment for approximately 3 months in clinic patients 20 to 70 years old with lipedema. The main questions it aims to answer are: does the leg circumference decrease and does the participants' overall wellbeing improve?

Participants will:

• Have physical examinations and measurements at baseline and 3 month visit
• Complete wellbeing self-assessments at baseline and 3 month visit
• Have blood drawn for chemical markers at baseline and 3 month visit
• Complete four visits total

Inclusion criteria

• established diagnosis of lipedema for at least one (1) year
• women, ages 20 to 70 years
• score of at least 4 out of 10 on self-assessment on a 0-10 scale (10=worst) for overall sense of well being
• be willing to stop compression therapy for one week prior to each visit

Exclusion criteria

• other forms of leg enlargement, including lymphedema
• any primary systemic vasculopathy
• history of exposure to Vasculera or other diosmin containing medication within one (1) year of the screening visit
• concomitant use of warfarin, platelet inhibitors, factor Xa inhibitors or any medication intended to reduce blood coagulability
• concomitant use of diclofenac, metronidazole or chlorzoxazone
• uncontrolled hypertension (BP>170/110), unstable cardiac disease, active skin ulceration
• any other disease or condition that, in the opinion of the investigator, might put the
• subject at risk by participation in this study OR confound evaluation of response to Vasculera
• history of substance abuse within one (1) year of the screening visit or of current alcohol consumption more than one (1) unit daily. For purposes of this study, a unit of alcohol will be considered to be 12 oz of beer, 6 oz of wine or 1 oz of hard spirits.